We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TECH Stock Falls on Q1 Earnings Meet, Revenues Miss, Margins Up
Read MoreHide Full Article
Key Takeaways
Bio-Techne posted Q1 EPS of 42 cents, matching estimates and flat year over year.
TECH revenues fell 1% to $286.6 million, missing expectations and triggering a 7.5% stock drop.
TECH's gross and operating margins expanded, supported by lower costs and stable segment performance.
Bio-Techne Corporation (TECH - Free Report) reported first-quarter fiscal 2026 adjusted earnings per share (EPS) of 42 cents, which matched the Zacks Consensus Estimate. The bottom line remained flat on a year-over-year basis.
The quarter's adjustments eliminated the impact of certain one-time items, including amortization of intangibles and Wilson Wolf intangible assets, and restructuring and restructuring-related costs, among others.
GAAP loss per share was 24 cents compared to EPS of 21 cents in the prior-year quarter.
TECH's Revenues in Detail
In the fiscal first quarter, Bio-Techne registered net sales of $286.6 million, down 1% year over year on a reported basis and on an organic basis. The figure missed the Zacks Consensus Estimate by 0.9%.
Following the earnings announcement, shares of TECH dipped 7.5% in pre-market trading today. The fall can be attributed to investor reaction to the quarterly revenue decline.
Segmental Analysis of TECH’s Q1 Revenues
The company reports under two business segments — Protein Sciences, and Diagnostics and Spatial Biology (formerly Diagnostics and Genomics).
Within Protein Sciences, Bio-Techne recorded revenues of $202.2 million, down 1% year over year (down 3% organically). In fiscal 2024, a business within this segment met the criteria as held-for-sale, excluded from its operating results.
Within Diagnostics and Spatial Biology, sales decreased 4% year over year to $79.5 million (up 3% organically) in the fiscal first quarter. Within this, the Exosome Diagnostics business met the held-for-sale criteria, excluded from its operating results.
TECH’s Q1 Margins
Bio-Techne’s gross profit rose 2.8% to $188.1 million. The gross margin expanded 242 basis points (bps) to 65.6% on a 7.5% fall in the cost of sales.
Selling, general and administrative expenses declined 2.5% to $116.2 million. Research and development expenses totaled $24.2 million, up 1.6% year over year.
The company generated an operating profit of $47.7 million in the fiscal first quarter compared with the year-ago quarter’s figure of $40 million. The operating margin expanded 282 bps to 16.6% during the quarter.
Bio-Techne exited the fiscal first quarter of 2026 with cash and equivalents of $145 million compared with $162.2 million at the end of fiscal fourth-quarter 2025. Long-term debt obligations totaled $300 million compared with $346 million at the end of the fiscal fourth-quarter 2025.
Net cash provided by operating activities was $27.6 million at the end of the fiscal first quarter compared with $63.9 million a year ago.
Our Take on Bio-Techne’s Results
Bio-Techne ended the first quarter of fiscal 2026 with earnings matching estimates but revenues missing the same. Quarterly revenues declined slightly, however, signs of stabilization in the U.S. academic market and continued strength among large pharmaceutical customers were evident. ProteinSimple’s analytical solutions sustained strong momentum, while Spatial Biology showed stabilization with early signs of accelerating growth ahead. In the Cell Therapy segment, several key customers received FDA Fast Track Designation, potentially expediting clinical development and approval processes.
Meanwhile, the expansion of both gross and operating margins remains encouraging.
TECH's Zacks Rank and Key Picks
Bio-Techne currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Medpace Holdings (MEDP - Free Report) , IDEXX Laboratories (IDXX - Free Report) and Boston Scientific (BSX - Free Report) .
Medpace, currently sporting a Zacks Rank #1 (Strong Buy), reported a third-quarter 2025 EPS of $3.86, which surpassed the Zacks Consensus Estimate by 10.29%. Revenues of $659.9 million beat the Zacks Consensus Estimate by 3.04%. You can see the complete list of today’s Zacks #1 Rank stocks here.
MEDP has an estimated earnings growth rate of 17.1% for 2025 compared with the industry’s 16.6% growth. The company beat on earnings in each of the trailing four quarters, the average surprise being 14.28%.
IDEXX, carrying a Zacks Rank #2 (Buy) at present, posted a third-quarter 2025 adjusted EPS of $3.40, which exceeded the Zacks Consensus Estimate by 8.3%. Revenues of $1.11 billion topped the Zacks Consensus Estimate by 3.2%.
IDXX has an estimated historical earnings growth rate of 14.9% compared with the industry’s 10.1% growth. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 6.08%.
Boston Scientific, currently carrying a Zacks Rank #2, reported a third-quarter 2025 adjusted EPS of 75 cents, which surpassed the Zacks Consensus Estimate by 5.6%. Revenues of $5.07 billion topped the Zacks Consensus Estimate by 1.9%.
BSX has an estimated long-term earnings growth rate of 16.4% compared with the industry’s 13.5% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 7.36%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
TECH Stock Falls on Q1 Earnings Meet, Revenues Miss, Margins Up
Key Takeaways
Bio-Techne Corporation (TECH - Free Report) reported first-quarter fiscal 2026 adjusted earnings per share (EPS) of 42 cents, which matched the Zacks Consensus Estimate. The bottom line remained flat on a year-over-year basis.
The quarter's adjustments eliminated the impact of certain one-time items, including amortization of intangibles and Wilson Wolf intangible assets, and restructuring and restructuring-related costs, among others.
GAAP loss per share was 24 cents compared to EPS of 21 cents in the prior-year quarter.
TECH's Revenues in Detail
In the fiscal first quarter, Bio-Techne registered net sales of $286.6 million, down 1% year over year on a reported basis and on an organic basis. The figure missed the Zacks Consensus Estimate by 0.9%.
Following the earnings announcement, shares of TECH dipped 7.5% in pre-market trading today. The fall can be attributed to investor reaction to the quarterly revenue decline.
Segmental Analysis of TECH’s Q1 Revenues
The company reports under two business segments — Protein Sciences, and Diagnostics and Spatial Biology (formerly Diagnostics and Genomics).
Within Protein Sciences, Bio-Techne recorded revenues of $202.2 million, down 1% year over year (down 3% organically). In fiscal 2024, a business within this segment met the criteria as held-for-sale, excluded from its operating results.
Within Diagnostics and Spatial Biology, sales decreased 4% year over year to $79.5 million (up 3% organically) in the fiscal first quarter. Within this, the Exosome Diagnostics business met the held-for-sale criteria, excluded from its operating results.
TECH’s Q1 Margins
Bio-Techne’s gross profit rose 2.8% to $188.1 million. The gross margin expanded 242 basis points (bps) to 65.6% on a 7.5% fall in the cost of sales.
Selling, general and administrative expenses declined 2.5% to $116.2 million. Research and development expenses totaled $24.2 million, up 1.6% year over year.
The company generated an operating profit of $47.7 million in the fiscal first quarter compared with the year-ago quarter’s figure of $40 million. The operating margin expanded 282 bps to 16.6% during the quarter.
Bio-Techne Corp Price, Consensus and EPS Surprise
Bio-Techne Corp price-consensus-eps-surprise-chart | Bio-Techne Corp Quote
Bio-Techne’s Capital Structure
Bio-Techne exited the fiscal first quarter of 2026 with cash and equivalents of $145 million compared with $162.2 million at the end of fiscal fourth-quarter 2025. Long-term debt obligations totaled $300 million compared with $346 million at the end of the fiscal fourth-quarter 2025.
Net cash provided by operating activities was $27.6 million at the end of the fiscal first quarter compared with $63.9 million a year ago.
Our Take on Bio-Techne’s Results
Bio-Techne ended the first quarter of fiscal 2026 with earnings matching estimates but revenues missing the same. Quarterly revenues declined slightly, however, signs of stabilization in the U.S. academic market and continued strength among large pharmaceutical customers were evident. ProteinSimple’s analytical solutions sustained strong momentum, while Spatial Biology showed stabilization with early signs of accelerating growth ahead. In the Cell Therapy segment, several key customers received FDA Fast Track Designation, potentially expediting clinical development and approval processes.
Meanwhile, the expansion of both gross and operating margins remains encouraging.
TECH's Zacks Rank and Key Picks
Bio-Techne currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Medpace Holdings (MEDP - Free Report) , IDEXX Laboratories (IDXX - Free Report) and Boston Scientific (BSX - Free Report) .
Medpace, currently sporting a Zacks Rank #1 (Strong Buy), reported a third-quarter 2025 EPS of $3.86, which surpassed the Zacks Consensus Estimate by 10.29%. Revenues of $659.9 million beat the Zacks Consensus Estimate by 3.04%. You can see the complete list of today’s Zacks #1 Rank stocks here.
MEDP has an estimated earnings growth rate of 17.1% for 2025 compared with the industry’s 16.6% growth. The company beat on earnings in each of the trailing four quarters, the average surprise being 14.28%.
IDEXX, carrying a Zacks Rank #2 (Buy) at present, posted a third-quarter 2025 adjusted EPS of $3.40, which exceeded the Zacks Consensus Estimate by 8.3%. Revenues of $1.11 billion topped the Zacks Consensus Estimate by 3.2%.
IDXX has an estimated historical earnings growth rate of 14.9% compared with the industry’s 10.1% growth. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 6.08%.
Boston Scientific, currently carrying a Zacks Rank #2, reported a third-quarter 2025 adjusted EPS of 75 cents, which surpassed the Zacks Consensus Estimate by 5.6%. Revenues of $5.07 billion topped the Zacks Consensus Estimate by 1.9%.
BSX has an estimated long-term earnings growth rate of 16.4% compared with the industry’s 13.5% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 7.36%.